Dr George Au-Yeung
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
103 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.
DOI: 10.1038/s41467-026-71134-32026
Journal article
Real-world comparative outcomes of neoadjuvant chemotherapy with interval cytoreductive surgery versus primary cytoreductive surgery in epithelial ovarian cancer: insights from the australian ovarian cancer study (AOCS)
DOI: 10.1016/j.ijgc.2025.1030762025
Journal article
EXPLORING TRANSCRIPTIONAL SUBTYPES AND IMMUNE MARKERS IN BEACON; PHASE II STUDY OF ATEZOLIZUMAB, BEVACIZUMAB, COBIMETINIB IN PLATINUM RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER
DOI: 10.1016/j.ijgc.2025.1025002025
Journal article
954P A randomized phase II study of autogene cevumeran plus pembrolizumab (pembro) versus pembro in 1L advanced melanoma (IMcode001)
DOI: 10.1016/j.annonc.2025.08.15232025
Journal article
1694eP Real-world induction targeted therapy (TT) with immune checkpoint inhibitor (ICI) therapy switch in advanced BRAF-mutant melanoma: A multi-institutional study
DOI: 10.1016/j.annonc.2025.08.23212025
Journal article
233eP Association between circulating tumour DNA and FDG-PET as biomarkers of response to neoadjuvant therapy in stage III melanoma
DOI: 10.1016/j.annonc.2025.08.6632018
Research Grant
Investigating the Immune Landscape and Gene Expression Profile of End-Stage High Grade Serous Ovarian Cancer
RECENT SCHOLARLY WORKS
2025
Journal article
Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort
DOI: 10.1016/j.modpat.2025.1007762025
Journal article
Abstract P4-10-16: INX-315, an oral, potent and selective CDK2 inhibitor in patients with CDK4/6 inhibitor resistant ER /HER2- breast cancer or CCNE1 amplified solid tumors: phase 1 monotherapy dose escalation
DOI: 10.1158/1557-3265.sabcs24-p4-10-162025
Journal article
Patient-reported acute and chronic toxicities from adjuvant therapies post resection of melanoma.
DOI: 10.1200/jco.2025.43.16_suppl.e215682025
Conference Proceedings
Financial toxicity and employment outcomes in people with melanoma receiving adjuvant therapies.
DOI: 10.1200/jco.2025.43.16_suppl.9577